Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin A versus corticosteroid injection for knee osteoarthritis
ACTRN12621001622897Phase 3Not yet recruiting
- Sponsor
- Stephanie Babic
- Start
- Feb 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of botulinum toxin type A and triamcinolone acetonide in knee osteoarthritis (OA) (2 arms), sponsored by Stephanie Babic. Primary endpoints: Pain level by Visual Analogue Scale, Function by Oxford Knee Score and 1 more. Planned start Feb 2022; status: not yet recruiting.
02
Drugs
botulinum toxin type Atriamcinolone acetonide
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on ACTRN12621001622897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001622897.